# Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control

> **NCT03096392** · PHASE2 · COMPLETED · sponsor: **Diasome Pharmaceuticals** · enrollment: 46 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** HDV insulin lispro 100 UNT/ML
- **DRUG:** Insulin Lispro 100 UNT/ML

## Key facts

- **NCT ID:** NCT03096392
- **Lead sponsor:** Diasome Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-18
- **Primary completion:** 2017-11-15
- **Final completion:** 2018-03-18
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2018-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03096392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03096392, "Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03096392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*